Tonix Pharmaceuticals (NASDAQ:TNXP) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a research report released on Thursday morning. The firm issued a hold rating on the stock.

Tonix Pharmaceuticals Stock Up 8.9 %

TNXP opened at $0.28 on Thursday. The company has a quick ratio of 2.81, a current ratio of 3.33 and a debt-to-equity ratio of 0.07. Tonix Pharmaceuticals has a twelve month low of $0.12 and a twelve month high of $12.48. The company has a market cap of $52.09 million, a PE ratio of -0.01 and a beta of 2.02. The company has a 50-day moving average price of $0.25 and a 200 day moving average price of $0.32.

Tonix Pharmaceuticals (NASDAQ:TNXP) last released its earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. The business had revenue of $2.82 million for the quarter, compared to the consensus estimate of $2.63 million. Sell-side analysts expect that Tonix Pharmaceuticals will post -17.63 earnings per share for the current fiscal year.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.